ACT 453859

Drug Profile

ACT 453859

Alternative Names: ACT-453859

Latest Information Update: 08 Jul 2015

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Cardiovascular therapies
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders

Most Recent Events

  • 01 Apr 2015 ACT 453859 is still in phase I trials for Cardiovascular disorders in Canada
  • 01 Apr 2012 Actelion completes a phase I trial in Cardiovascular disorders (In volunteers) in Canada (NCT02381496)
  • 01 Dec 2011 Phase-I clinical trials in Cardiovascular disorders (In volunteers) in Canada (PO) (NCT02381496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top